🚀 VC round data is live in beta, check it out!
Coegin Pharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Coegin Pharm and similar public comparables like BioLineRx, Annexin Pharmaceuticals, Reviva Pharmaceuticals, Biomind Labs and more.
Coegin Pharm Overview
About Coegin Pharm
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
Founded
2019
HQ
Employees
1
Website
Sectors
Financials (FY)
EV
$10M
Coegin Pharm Financials
Coegin Pharm reported last fiscal year revenue of $9K and negative EBITDA of ($2M).
In the same fiscal year, Coegin Pharm generated ($84K) in gross profit, ($2M) in EBITDA losses, and had net loss of ($2M).
Coegin Pharm P&L
In the most recent fiscal year, Coegin Pharm reported revenue of $9K and EBITDA of ($2M).
Coegin Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $9K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($84K) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (975%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (22056%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (25890%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (25946%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Coegin Pharm Stock Performance
Coegin Pharm has current market cap of $11M, and enterprise value of $10M.
Market Cap Evolution
Coegin Pharm's stock price is $0.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $11M | 0.3% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCoegin Pharm Valuation Multiples
Coegin Pharm trades at 1200.2x EV/Revenue multiple, and (5.4x) EV/EBITDA.
Coegin Pharm Financial Valuation Multiples
As of April 19, 2026, Coegin Pharm has market cap of $11M and EV of $10M.
Equity research analysts estimate Coegin Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Coegin Pharm has a P/E ratio of (5.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | $10M | XXX | $10M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1200.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (4.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (123.1x) | XXX | XXX | XXX |
| P/E | — | XXX | (5.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Coegin Pharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Coegin Pharm Margins & Growth Rates
Coegin Pharm's revenue in the last fiscal year grew by —.
Coegin Pharm's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.
Coegin Pharm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (22056%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (14%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 24915% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Coegin Pharm Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Coegin Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| BioLineRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Annexin Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Reviva Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Biomind Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Chemomab Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Coegin Pharm M&A Activity
Coegin Pharm acquired XXX companies to date.
Last acquisition by Coegin Pharm was on XXXXXXXX, XXXXX. Coegin Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Coegin Pharm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCoegin Pharm Investment Activity
Coegin Pharm invested in XXX companies to date.
Coegin Pharm made its latest investment on XXXXXXXX, XXXXX. Coegin Pharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Coegin Pharm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Coegin Pharm
| When was Coegin Pharm founded? | Coegin Pharm was founded in 2019. |
| Where is Coegin Pharm headquartered? | Coegin Pharm is headquartered in Sweden. |
| How many employees does Coegin Pharm have? | As of today, Coegin Pharm has over 1 employees. |
| Is Coegin Pharm publicly listed? | Yes, Coegin Pharm is a public company listed on Nasdaq Global Market. |
| What is the stock symbol of Coegin Pharm? | Coegin Pharm trades under COEGIN ticker. |
| When did Coegin Pharm go public? | Coegin Pharm went public in 2018. |
| Who are competitors of Coegin Pharm? | Coegin Pharm main competitors are BioLineRx, Annexin Pharmaceuticals, Reviva Pharmaceuticals, Biomind Labs. |
| What is the current market cap of Coegin Pharm? | Coegin Pharm's current market cap is $11M. |
| What is the current revenue of Coegin Pharm? | Coegin Pharm's last fiscal year revenue is $9K. |
| What is the current EV/Revenue multiple of Coegin Pharm? | Current revenue multiple of Coegin Pharm is 1200.2x. |
| Is Coegin Pharm profitable? | No, Coegin Pharm is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.